Amyloid {beta}42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1

• Published in: The Journal of neuroscience 2001-01, Vol.21 (2), p.123
• Main Authors: Le, Yingying, Gong, Wanghua, Tiffany, H. Lee, Tumanov, Alexei, Nedospasov, Sergei, Shen, Weiping, Dunlop, Nancy M, Gao, Ji-Liang, Murphy, Philip M, Oppenheim, Joost J, Wang, Ji Ming
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Amyloid beta-Peptides - metabolism; Amyloid beta-Peptides - pharmacology; Animals; Brain - metabolism; Brain - pathology; Calcium - metabolism; Cell Line; Cell Movement - drug effects; Chemotaxis - drug effects; Dose-Response Relationship, Drug; Gene Expression; Gene Products, nef - pharmacology; GTP-Binding Proteins - antagonists & inhibitors; GTP-Binding Proteins - metabolism; Humans; In Situ Hybridization; Kidney - cytology; Kidney - drug effects; Kidney - metabolism; Monocytes - cytology; Monocytes - drug effects; Monocytes - metabolism; N-Formylmethionine Leucyl-Phenylalanine - pharmacology; Peptide Fragments - metabolism; Peptide Fragments - pharmacology; Rats; Receptors, Formyl Peptide; Receptors, Immunologic - genetics; Receptors, Immunologic - metabolism; Receptors, Lipoxin; Receptors, Peptide - genetics; Receptors, Peptide - metabolism; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - metabolism; RNA, Messenger - metabolism; Signal Transduction - drug effects; Transfection; Virulence Factors, Bordetella - pharmacology
• ISSN: 0270-6474; 1529-2401
• DOI: 10.1523/jneurosci.21-02-j0003.2001

Amyloid beta (Abeta) is a major contributor to the pathogenesis of Alzheimer's disease (AD). Although Abeta has been reported to be directly neurotoxic, it also causes indirect neuronal damage by activating mononuclear phagocytes (microglia) that accumulate in and around senile plaques. In this study, we show that the 42 amino acid form of beta amyloid peptide, Abeta(42), is a chemotactic agonist for a seven-transmembrane, G-protein-coupled receptor named FPR-Like-1 (FPRL1), which is expressed on human mononuclear phagocytes. Moreover, FPRL1 is expressed at high levels by inflammatory cells infiltrating senile plaques in brain tissues from AD patients. Thus, FPRL1 may mediate inflammation seen in AD and is a potential target for developing therapeutic agents.